Thinking of the adult patients with

Thinking of the adult patients with EGPA you’ve managed in the past 12 months, approximately how many have previously received Nucala (mepolizumab) for their EGPA but are no longer on this treatment?You mentioned that patients were previously receiving Nucala (mepolizumab) for their EGPA.How many patients discontinued use due to the following reasons?State the number of patients next to each reason for discontinuationInsufficient response (partial response, or primary nonresponse)Loss of response (secondary nonresponse)No longer necessary/patient’s disease can be controlled without itInjection fatigueInjection site reactionsor this next question, we want to understand what features of a biologic treatment for EGPA are most important to you when deciding on which one to use.You are going to see a total of 6 sets of treatment features, with 5 treatment features shown each time.Safety/tolerability concernsCost/Financial considerationsLack of patient compliance